The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...
Researchers delivered a dose of the “love hormone” oxytocin via a nasal spray to participants and found that it decreased ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand ... as Spravato can provide rapid and durable symptom relief. The drug, available only under strict medical supervision ...